Brief: Neurobo Pharmaceuticals Submits IND Application To FDA For Phase 1 Clinical Trial Of DA-1726

MetaVia

28/12/2023 14:34

Dec 28 (Reuters) - Neurobo Pharmaceuticals Inc  NRBO.O :
    * NEUROBO PHARMACEUTICALS SUBMITS IND APPLICATION TO THE FDA
FOR A
PHASE 1 CLINICAL TRIAL OF DA-1726 FOR THE TREATMENT OF OBESITY
    * NEUROBO PHARMACEUTICALS SUBMITS IND APPLICATION TO THE FDA
FOR A
PHASE 1 CLINICAL TRIAL OF DA-1726 FOR THE TREATMENT OF OBESITY
    * NEUROBO PHARMACEUTICALS - LOOK TO INITIATING CLINICAL
DEVELOPMENT FOR DA-1726, WITH FIRST DOSE EXPECTED TO BE
ADMINISTERED IN FIRST HALF OF 2024

Source text for Eikon:  ID:nPn6DKgzLa 
Further company coverage:  NRBO.O 

 ((Reuters.Briefs@thomsonreuters.com;))